A5064462264- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Celiac Disease Research and Management
- Helicobacter pylori-related gastroenterology studies
- SARS-CoV-2 detection and testing
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- IL-33, ST2, and ILC Pathways
- Monoclonal and Polyclonal Antibodies Research
- Bacteriophages and microbial interactions
- Immune Cell Function and Interaction
- Blood groups and transfusion
- Asthma and respiratory diseases
- Eosinophilic Esophagitis
- Rheumatoid Arthritis Research and Therapies
- Antibiotics Pharmacokinetics and Efficacy
- Research on Leishmaniasis Studies
- Synthesis and biological activity
- Autoimmune and Inflammatory Disorders Research
- Dermatology and Skin Diseases
KU Leuven
2018-2024
Trellis Bioscience (United States)
2024
Rega Institute for Medical Research
2019
Ustekinumab, an anti-IL12/23p40 monoclonal antibody, has been approved for Crohn's disease [CD]. Real-life data in CD patients receiving ustekinumab intravenously [IV] during induction, followed by subcutaneous [SC] maintenance, are lacking. We assessed efficacy of and studied exposure-response correlations.We performed a prospective study 86 predominantly refractory or intolerant to anti-tumour necrosis factor agents and/or vedolizumab. All received 6 mg/kg IV with 90 mg SC every 8 weeks...
The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti-vedolizumab antibodies (AVA) are frequently underestimated because most assays not drug-tolerant and unable to detect antidrug while there is drug in the circulation. This study aimed explore which antibody assay best suited AVA investigated vedolizumab inflammatory bowel disease (IBD) patients discontinuing therapy.A affinity capture elution (ACE) was developed for measurement presence compared with...
Abstract Mice deficient in IFN-γ (IFN-γ knockout [KO] mice) develop a systemic inflammatory syndrome response to CFA, contrast CFA-challenged wild-type (WT) mice who only mild inflammation. Symptoms KO resemble juvenile idiopathic arthritis (sJIA), childhood immune disorder of unknown cause. Dysregulation innate cells is considered be important the disease pathogenesis. In this study, we used murine model investigate role NK pathogenesis sJIA. displayed an aberrant balance activating and...
Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management. Unfortunately, SARS-CoV-2 variants escape several of these recently approved mAbs, highlighting the need for additional discovery and development. In a convalescent patient COVID-19, we identified six classified in four epitope groups, that potently neutralized D614G, beta, gamma, delta infection vitro, three mAbs omicron as well....
An association between vedolizumab (VDZ) trough concentrations and therapeutic outcome has been observed in patients with inflammatory bowel diseases. VDZ samples are typically collected via venous sampling for drug monitoring (TDM), but can alternatively be dried blood spot (DBS) samples, which used intensive to investigate pharmacokinetic profiles. Therefore, we have developed a DBS method determining validated this by comparing measurements paired patient samples. First, was spiked...
Cost-effective use of biologicals is important. As drug concentrations have been linked to clinical outcomes, monitoring a valuable tool guide decision-making. A concentration-response relationship for ustekinumab at trough uncertain owing the contradictory results reported.To investigate between 4-week postinjection and response in patients with psoriasis.Forty-nine moderate-to-severe psoriasis treated 45 mg or 90 every 12 weeks ≥ 16 were included. Ustekinumab serum anti-ustekinumab...
Abstract Background and Aims Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed investigate tissue questioned whether insufficient could explain non-response UC serum concentrations. Methods A paired sample colonic mucosal biopsy was collected from 40 [20 endoscopic responders, 20 non-responders] at week 14 of treatment. Vedolizumab, soluble [s]-mucosal addressin cell adhesion molecule-1 [MAdCAM-1],...
Adeno-associated virus (AAV) is a non-pathogenic used as delivery vehicle to transfer therapeutic genes into patients. Accurate quantification of AAV genome copy number in vector preparations essential for bioprocess optimization and dosage calculation both preclinical clinical studies AAV-based gene therapy products. Currently, consensus protocol viral titration lacking. Here, we present digital droplet PCR (dd_PCR) the genomes purified samples. Samples are treated with DNase I eliminate...
Abstract Background Therapeutic drug monitoring of ustekinumab (UST), a monoclonal antibody directed against the p40 subunit IL12/23, can serve as tool to identify underexposed Crohn’s disease (CD) patients, UST concentrations have been linked treatment response. Drug are most often measured when patient is losing To reduce risk loss response, could be upfront predict chance achieving response later on and optimising if necessary. Identification optimal time point measure levels that...
Abstract Background Multiple studies have reported the association between vedolizumab serum concentrations and endoscopic outcomes in patients with ulcerative colitis (UC). However, little is known about drug consumption tissue relationship mucosal inflammation. This study aimed to investigate of UC correlation their inflammatory state levels. Methods A paired sample colonic biopsy were collected 36 at week 14 treatment. In non-responders, defined as a Mayo subscore ≥2, inflamed biopsies...
Abstract Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management. Unfortunately, SARS-CoV-2 variants can escape several of these recently approved mAbs, highlighting the need for additional discovery and development. In a convalescent patient, we identified six classified in four epitope groups, that potently neutralized Wuhan, alpha, beta, gamma delta infection vitro . hamsters, mAbs 3E6...
Since not all Crohn's disease (CD) patients respond adequately to ustekinumab therapy, biomarkers could aid monitor treatment response and optimize therapeutic outcomes.To explore the dynamics of serum biomarker concentrations in CD patients.Retrospective, exploratory study evaluate cytokines acute phase proteins their relation endoscopic remission during treatment.Serum 16 including were measured using Mesoscale Discovery Platform healthy controls (n = 13), 61) at baseline (week 0), week 8...
The pivotal GEMINI trials reported low immunogenicity (4%) of vedolizumab during treatment. However, 16 weeks after treatment discontinuation, 10% patients were anti-vedolizumab antibody (AVA) positive using a drug-sensitive assay. AVA are frequently underestimated since most assays not drug-tolerant and unable to detect anti-drug antibodies while there is drug in the circulation. This study aimed explore which assay best suited investigated inflammatory bowel disease (IBD) discontinuing...
Abstract Background Various studies have shown an association between ustekinumab serum concentrations and treatment response in patients with Crohn’s disease (CD). However, the time point at which this concentration is most informative for long-term outcome unknown. Dried blood spot (DBS) sampling allows remote collection of measurements various points. By use method, current study aimed to evaluate exposure-response relationship throughout first 24 weeks investigate points levels could...